Muscimol
In clinical developmentAlso known as 5-(aminomethyl)-3(2H)-isoxazolone.
Recent clinical, regulatory, research and industry developments relating to this drug.
Trial of Intracerebral Infusion in Patients With Medically Intractable Epilepsy
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- The Journal of neuroscience : the official journal of the Society for Neuroscience1
- Boyce LH1
- Davis MB1
- Kriegstein AR1
- Owens DF1
- College of Physicians and Surgeons of Columbia University1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Frequently co-studied with Muscimol in the research literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials